• Home
  • About Us
    • Company Profile
    • Enterprise Honor
    • Enterprise Qualification
    • Corporate Shareholder
  • Science & Innovation
    • Molecular Glue
    • GLUETAC
    • Degrader-Antibody Conjugates
    • Journal Articles
  • Pipeline
    • GT919
    • GT929
    • GT818
    • GT820
  • Partnerships
    • Local Cooperation
    • Out Licensing
    • Global Cooperation
    • University Cooperation
  • Subject Recruitment
    • Multiple myeloma
    • Non-Hodgkin’s lymphoma
  • Talent Strategy
    • Talent concept
    • Employee honor
    • Employee Showcase
    • Welfare system
    • Job Openings
    • Talent scheme
  • Press Releases
    • R&D advancements
    • Technology Platform
    • Media Coverage
  • Contact Us
    • China
    • USA
    • Canada
  • Home
  • About Us
    • Company Profile
    • Enterprise Honor
    • Enterprise Qualification
    • Corporate Shareholder
  • Science & Innovation
    • Molecular Glue
    • GLUETAC
    • Degrader-Antibody Conjugates
    • Journal Articles
  • Pipeline
    • GT919
    • GT929
    • GT818
    • GT820
  • Partnerships
    • Local Cooperation
    • Out Licensing
    • Global Cooperation
    • University Cooperation
  • Subject Recruitment
    • Multiple myeloma
    • Non-Hodgkin’s lymphoma
  • Talent Strategy
    • Talent concept
    • Employee honor
    • Employee Showcase
    • Welfare system
    • Job Openings
    • Talent scheme
  • Press Releases
    • R&D advancements
    • Technology Platform
    • Media Coverage
  • Contact Us
    • China
    • USA
    • Canada
中文English
中文English
Slide 1
Partnerships


    Enterprise Email

    Gluetacs Therapeutics (Shanghai) Co., Ltd.

    Building 20, Lane 218, Haiji 6th Road, Pudong District, Shanghai, China

    Zip Code: 201306

    Tel: +86-21-58162368

    Copyright © Gluetacs Therapeutics (Shanghai) Co., Ltd. 沪ICP备2021038033号-3

    沪公网安备 31011502001234号

    Wechat Offical Account

    Scan & Follow Us